Calithera Biosciences 주식 가격. CALA - 주식 시세, 차트, 과거 거래, 주식 채팅, 재무.

다우존스 지수

브라질 증권 거래소, NASDAQ, NYSE, AMEX, LSE 등 주요 거래소에서의 다양한 실시간 주식 시세를 모니터링합니다.

등록

홈
인베스팅
주식
미국
NASDAQ
Calithera Biosciences Inc (CALA) 시세

Calithera Biosciences Inc (CALA)

0.20

0.00

(0.00%)

마감 03 12월 6:00AM

0.00

0.00

(0.00%)

시간외 거래: -

포트폴리오 강화: 실시간 토론 및 실행 가능한 거래 아이디어.

가격

0.20

매수가

0.16

매도가

0.35

거래량

-

0.00 일간 변동폭 0.00

0.00 52주 범위 0.00

market_cap

전일 종가

0.20

개장가

-

최근 거래 시간

마지막 거래 시간

재정 규모

-

VWAP

-

평균 볼륨(3m)

-

발행 주식

4,872,497

배당수익률

-

주가수익률

0.00

주당순이익(EPS)

-4.37

매출

-

순이익

-21.29M

Calithera Biosciences Inc is a clinical-stage pharmaceutical company. The business activity of the firm functions through the region of the US. It focuses on discovering and developing small molecule drugs directed against tumor and immune cell targets that control key metabolic pathways in the tumo... Calithera Biosciences Inc is a clinical-stage pharmaceutical company. The business activity of the firm functions through the region of the US. It focuses on discovering and developing small molecule drugs directed against tumor and immune cell targets that control key metabolic pathways in the tumor microenvironment. Its lead product candidate is CB-839, an inhibitor of glutaminase for the treatment of solid tumors. Its other product candidate, CB-1158, is being developed for hematology and oncology indications. 더 보기

섹터

Pharmaceutical Preparations

산업

Pharmaceutical Preparations

웹사이트

www.calithera.com

본부

Wilmington, Delaware, USA

설립됨

-

Calithera Biosciences Announces Update on Complete Liquidation and Dissolution

SOUTH SAN FRANCISCO, Calif., June 29, 2023 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (OTC: “CALA”). Calithera Biosciences, Inc. (the “Company”) announced that it was unable to achieve a...

Calithera Biosciences Announces Update on Complete Liquidation and Dissolution

SOUTH SAN FRANCISCO, Calif., May 19, 2023 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (OTC: CALA) (the “Company”) announced that it intends to hold a special meeting of stockholders on or...

Calithera Biosciences Announces Board Approval of Complete Liquidation and Dissolution

SOUTH SAN FRANCISCO, Calif., Jan. 09, 2023 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), today announced that its Board of Directors has determined, after extensive...

Calithera Biosciences Reports Third Quarter 2022 Financial Results and Business Update

SOUTH SAN FRANCISCO, Calif., Nov. 14, 2022 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage, precision-oncology biopharmaceutical company, today announced its...

Calithera Biosciences to Report Third Quarter 2022 Financial Results on Monday, November 14, 2022

SOUTH SAN FRANCISCO, Calif., Nov. 08, 2022 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage, precision-oncology biopharmaceutical company, today announced...

Calithera Receives FDA Fast Track Designation for Sapanisertib for the Treatment of NRF2-mutated Squamous Lung Cancer

SOUTH SAN FRANCISCO, Calif., Oct. 03, 2022 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage, precision oncology biopharmaceutical company, today announced that...

Calithera to Present at the H.C. Wainwright 24th Annual Global Investment Conference

SOUTH SAN FRANCISCO, Calif., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage, precision oncology biopharmaceutical company, today announced that...

Calithera Biosciences Reports Second Quarter 2022 Financial Results and Recent Highlights

SOUTH SAN FRANCISCO, Calif., Aug. 15, 2022 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage, precision-oncology biopharmaceutical company, today announced its...

Calithera Biosciences to Report Second Quarter 2022 Financial Results on Monday, August 15, 2022

SOUTH SAN FRANCISCO, Calif., Aug. 08, 2022 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage, precision-oncology biopharmaceutical company, today announced...

Calithera Biosciences Shares Progress in Sapanisertib and Mivavotinib Clinical Programs at Upcoming Lung Cancer and Lymphoma Conferences

-- Overview of phase 2 study evaluating SYK inhibitor mivavotinib in patients with relapsed/refractory non-GCB (ABC) diffuse large B-cell lymphoma -- -- First data from phase 1...

기간	변동	변동 %	시가	고가	저가	평균 일일 거래량	VWAP
1	0	0	0	0	0	0	0	CS
4	0	0	0	0	0	0	0	CS
12	0	0	0	0	0	0	0	CS
26	0	0	0	0	0	0	0	CS
52	0	0	0	0	0	0	0	CS
156	0	0	0	0	0	0	0	CS
260	0	0	0	0	0	0	0	CS

가장 활성
% 상승자
% 패자

기호	가격	볼륨
SNTISenti Biosciences Inc	US$ 10.09 (367.13%)	129.8M
PPBTPurple Biotech Ltd	US$ 8.359 (149.15%)	48.02M
GELSGelteq Ltd	US$ 3.8205 (92.95%)	1.41M
FOSLFossil Group Inc	US$ 2.35 (60.96%)	29.6M
FGLFounder Group Limited	US$ 4.48 (60.00%)	473.99k
MONDMondee Holdings Inc	US$ 0.375 (-47.20%)	2.89M
JYDJayud Global Logistics Ltd	US$ 0.6701 (-39.63%)	1.81M
TOIIWOncology Institute Inc	US$ 0.0122 (-35.45%)	929
IDAIT Stamp Inc	US$ 0.4565 (-33.84%)	12.88M
FOXXFoxx Development Holdings Inc	US$ 3.32 (-29.96%)	43.6k
SMCISuper Micro Computer Inc	US$ 42.00 (28.68%)	263.23M
XTIAXTI Aerospace Inc	US$ 0.04745 (5.68%)	177.38M
NVDANVIDIA Corporation	US$ 138.63 (0.27%)	170.53M
INTCIntel Corporation	US$ 23.93 (-0.50%)	150.48M
RGTIRigetti Computing Inc	US$ 3.035 (-0.49%)	134.81M

ALERTS100%to10000%GAIN

ALERTS100%to10000%GAIN 2 년 전

maybe soon will see something

ALERTS100%to10000%GAIN

ALERTS100%to10000%GAIN 2 년 전

maybe soon will see something

ALERTS100%to10000%GAIN

ALERTS100%to10000%GAIN 2 년 전

ALERTS100%to10000%GAIN

ALERTS100%to10000%GAIN 2 년 전

cala soon something

Renee

Renee 2 년 전

CALA delisted from the Nasdaq to the OTC:

https://otce.finra.org/otce/dailyList?viewType=Additions

kzivann

kzivann 2 년 전

CALA dissolving. https://quantisnow.com/insight/3950020

Mr. Zen

Mr. Zen 2 년 전

Calithera continued to advance multiple vacuolar protein sorting-associated protein 4A (VPS4A) and VPS4B inhibitors through lead optimization and plans to share updates on this program by the end of 2022.

Nealio

Nealio 2 년 전

CALA - continues upward. 100% gain in last month, very good swing play. Drug data was good...float is very low at 4.X M shares.

Nealio

Nealio 2 년 전

CALA in play! Drug data and earnings report. Should move even higher on this news.

Nealio

Nealio 2 년 전

Chart looks very good atm.

Nealio

Nealio 2 년 전

Could be the start of a big run; or not. We shall see; with recent good news, I like the chances. Good luck to all!

ttottip

ttottip 3 년 전

ttottip

ttottip 3 년 전

Good morning all! Hoping for a reversal today.

ttottip

ttottip 3 년 전

I'm not hesitating to buy at these levels!

bandit007

bandit007 3 년 전

Took a few here. $CALA

kzivann

kzivann 3 년 전

Moving after hours.

CALA

crudeoil24

crudeoil24 3 년 전

Calithera Biosciences shares are trading higher after Ladenburg Thalmann initiated coverage on the stock with a Buy rating and a $4 price target.

CALA

TheFinalCD

TheFinalCD 3 년 전

big move 45-74

$CALA

glens0

glens0 3 년 전

$CALA .58 w/ $3 price upgrade out by Leerink

Eagle1

Eagle1 3 년 전

crudeoil24

crudeoil24 3 년 전

Company discontinued its KEAPSAKE clinical trial.

Eagle1

Eagle1 3 년 전

Hi why the drop here?

0210

Calithera Biosciences CALA Q3 EPS $(0.15) Beats $(0.23) Estimate, Sales $6.75M, and a 53.13 percent increase over losses of $(0.32) per share from the same period last year.

4:42 pm ET November 9, 2021 (Benzinga)
Calithera Biosciences (NASDAQ:CALA) reported quarterly losses of $(0.15) per share which beat the analyst consensus estimate of $(0.23) by 34.78 percent. This is a 53.13 percent increase over losses of $(0.32) per share from the same period last year. The company reported $6.75 million in sales this quarter.

0210

right-on-the-money...-54% to $0.86-0.87, from $1.90 on 21x dmav (of only 1,082,848 daily moving average volume).

SOURCE: https://ih.advfn.com/stock-market/NASDAQ/calithera-biosciences-CALA/historical

willlbone

willlbone 3 년 전

Bid at 60% drop.

TheFinalCD

TheFinalCD 3 년 전

$CALA -40%

Calithera Biosciences, Inc. | Calithera Biosciences Announces Decision to Discontinue KEAPSAKE Clinical Trial

https://ir.calithera.com/news-releases/news-release-details/calithera-biosciences-announces-decision-discontinue-keapsake

Elgordo84

Elgordo84 4 년 전

I’m expecting earnings to be on the up tomorrow
Let’s go $CALA

Elgordo84

Elgordo84 4 년 전

Looks like no one is paying attention
$CALA I guess is you and me!!!
Perfect for the run
While no one is watching.......

Elgordo84

Elgordo84 4 년 전

Ok hello $CALA
I LIKE WHAT I SEE HERE!!!!
Let’s take this for a ride...
$CALA LETS GO —————>

trade-stock000

trade-stock000 4 년 전

Cala when is the data due date? Thx

oaps222

oaps222 4 년 전

Thanks for the info.
Geez~~, what a move. I wish I knew it last Thursday! LOL

In any event, congratulations, if you already got in ARTL!

trade-stock000

trade-stock000 4 년 전

A-R-T-L is the one to watch (: PT $8-10
Add on correction price, read few post over there abt data and cocrystal CBD molecules. Apart from that it's focused on Lipid therapy the next frontier in Oncology.

oaps222

oaps222 4 년 전

Very good point, but be careful. The market is crazy. I can see some (big?) corrections in the near future.

oaps222

oaps222 4 년 전

From the recent 13G Filings, Adage Capital has reported its 4,000,000 shares of CALA (5.67% ownership) on Jan 13, 2021.

trade-stock000

trade-stock000 4 년 전

Yeah but in Jan that was not much of an update, that´s why stock plummeted, company needs more time.

Jan option price rose becoz of that reason, now fade out. Will visit this ticker later, for now it´s waste of cash esp when whole market is running nut

oaps222

oaps222 4 년 전

Was it on Jan 15-17, not Feb 15-17?
http://www.calithera.com/wp-content/uploads/2021/01/Arginase-1158-203-Poster.pdf

trade-stock000

trade-stock000 4 년 전

IV surges in the event of future price move. $5 call for Feb 19 it seems someone very bullish abt this stock and bot calls. Article u cited it's from Jan-13th, today its 13th Feb (:, unless next week something comes out which is highly unlikely.

oaps222

oaps222 4 년 전

I was doing a DD on CALA and found the following. I don't quite understand it. Can you share your thoughts on this?
"Implied Volatility Surging for Calithera Biosciences (CALA) Stock Options"

https://finance.yahoo.com/news/implied-volatility-surging-calithera-biosciences-134001483.html

trade-stock000

trade-stock000 4 년 전

2.42 or lower test first before go up i hope

trade-stock000

trade-stock000 4 년 전

CALA on Feb 15-17 presenting Biliary-Tract Cancer-Data-could do-vroomvroom

jondoeuk

jondoeuk 4 년 전

ASH abstract https://ash.confex.com/ash/2020/webprogram/Paper137266.html

ClayTrader

ClayTrader 5 년 전

* * $CALA Video Chart 12-23-2019 * *

Link to Video - click here to watch the technical chart video

cashbyers

cashbyers 5 년 전

9.5M block trade today @ $4.45.. 17% stake or $42M investment...

ClayTrader

ClayTrader 5 년 전

* * $CALA Video Chart 11-19-19 * *

Link to Video - click here to watch the technical chart video

jonny_red

jonny_red 5 년 전

4 Penny Stocks To Watch In November After Latest Milestones

$GTBP $CALA $AVDL $BLCM

https://www.transparenttraders.me/2019/11/4-penny-stocks-to-watch-in-november.html

cashbyers

cashbyers 5 년 전

Long CALA @ $2.60

buypumps

buypumps 5 년 전

Conference call Monday also. Could push to 3.90 area.

Zmill

Zmill 5 년 전

TA of CALA https://msmoneymoves.com/2019/07/12/calithera-initiates-potential-buying-opportunity/

CashBowski

CashBowski 5 년 전

CALA going to close the gap today.

Zmill

Zmill 5 년 전

Research mentioning CALA https://wordpress.com/block-editor/post/msmoneymoves.com/11262

Calithera Biosciences

Delayed Upgrade Clock

도움 및 지원받기: kr-support@advfn.com

ADVFN 서비스 이용은 ADVFN의 이용약관에 동의하는 것입니다 이용약관